



Restasis® (cyclosporine) – First-time generic

- On February 3, 2022, [Viatris launched](#) an [AB-rated](#) generic version of Allergan's [Restasis \(cyclosporine\)](#) 0.05% ophthalmic emulsion preservative-free single-use vials.
 - The [FDA announced](#) Viatris' approval of generic Restasis on February 2, 2022.
- Restasis is approved to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
- Restasis is also available as a branded product ([Restasis Multidose™](#)) in a multi-dose preservative-free bottle.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2022 Optum, Inc. All rights reserved.